MS Re has undergone a period of significant growth in recent years and expects to top $4bn in GWP by 2025. CUO Charlie Goldie explains on Behind the Headlines that the company’s strategy is to deliver ...
17h
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial Results
Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver ...
Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback